

# Contents

About the authors	xii
Foreword	xiv
Reviewers	xv
Acknowledgements	xvi
About this resource	xvii
Guide to text	xix

## PART 1

### Introduction to pharmacology 1

#### 1 Drugs and medicines 1

*Kirsten Small, Roslyn Donnellan-Fernandez*

Introduction 2

1.1 Drugs and medicines 2

Characteristics of drugs, 2

1.2 Drug discovery and development 4

Where drugs come from, 4

Drugs sourced from natural or traditional remedies, 5

Standards and government regulation, 10

Stages of drug development, 10

1.3 Drug names and classifications 13

Drug names, 13

Chemical names, 13

Proprietary (trade or brand) names, 17

Drug classifications, 17

1.4 Drug information 18

Important drug information, 18

What users of medications want to know, 18

Official sources, pharmacopoeias and formularies, 18

Semi-official sources, 19

Other drug information sources, 20

#### 2 Clinical, ethical and legal foundations of pharmacotherapy 23

*Roslyn Donnellan-Fernandez, Kirsten Small*

2.1 Clinical aspects of pharmacotherapy 24

Quality use of medicines, 24

Modifying drug usage over time, 26

Roles of health professionals in QUM, 29

Drug prescriptions and formulations, 31

Teaching prescribing, 36

2.2 Ethical aspects of pharmacotherapy 36

Human rights, the basis for bioethics, 36

2.3 Legal aspects of pharmacotherapy 39

International law, 39

Regulation of drugs in Australia, 40

Regulation of drugs in New Zealand, 43

## PART 2

### Principles of pharmacology 48

#### 3 Molecular drug targets and pharmacodynamics 48

*Maryam Bazargan, Kirsten Small, Roslyn Donnellan-Fernandez*

Introduction 49

3.1 Drug specificity, selectivity, and affinity 49

3.2 Molecular drug targets 50

Transporters, 50

Ion channels, 50

Enzymes, 50

Receptors, 50

Second messengers, 51

Desensitisation and receptor turnover, 53

3.3 Pharmacodynamics 54

Drug target interactions, 54

Antagonists, 55

Allosteric effects, 56

Concentration–response relationship, 56

Potency, 57

Efficacy, 57

#### 4 Drug absorption, distribution, metabolism and excretion 61

*Maryam Bazargan, Kirsten Small*

Introduction 62

4.1 Drug absorption 62

Absorption across biological membranes, 63

Passive diffusion, 63

Carrier-mediated transport, 63

Variables affecting drug absorption, 63

Routes of drug administration, 65

Bioavailability, 68

Absorption of drugs during pregnancy, 69

4.2 Distribution 69

Plasma protein binding, 69

Hypoalbuminaemia, 70

Tissue binding, 70

Tissue-specific barriers to drug distribution, 70

Drug distribution in pregnancy, 70

Drug distribution in the fetus, 71

4.3 Drug elimination (metabolism and excretion) 72

Drug metabolism, 72

Variability in drug metabolism, 73

4.4 Excretion of drugs and drug metabolites	75	Disorders of menstruation, 102	
Hepatic uptake and biliary excretion, 75		Endometriosis, 102	
Renal excretion, 76		Polycystic ovary syndrome, 103	
Pulmonary excretion, 76		Hirsutism, 103	
4.5 Pharmacokinetics during pregnancy and early life	77	7.2 Female infertility	103
Renal excretion during pregnancy, 77		Preconception, 103	
Pharmacokinetic development during early life, 77		7.3 Pregnancy	106
<b>5 Pharmacokinetics and dosing regimen</b>	<b>79</b>	Maternal adaptations, 106	
<i>Maryam Bazargan, Kirsten Small</i>		Drug use in pregnancy, 106	
Introduction	80	Teratogenesis: causing abnormal fetal development, 107	
5.1 Plasma concentration–time profile of a drug	80	Database for prescribing medicines in pregnancy, 109	
5.2 Key pharmacokinetic concept: Clearance	80	7.4 Common conditions in pregnancy	110
Hepatic clearance, 82		Nausea and vomiting in pregnancy (NVP), 110	
Renal clearance, 83		Gastro-oesophageal reflux, 114	
The importance of clearance, 83		Constipation, 116	
5.3 Key pharmacokinetic concept: Volume of distribution	83	Candidiasis, 118	
5.4 Key pharmacokinetic concept: Half-life	84	Rh (D) immunoglobulin, 119	
Determinants of half-life, 85		7.5 Complementary and alternative medicines (CAMs)	120
5.5 Dosage measurements and calculations	86	Aromatherapy, 120	
Measurement systems, 86		Herbal medicines, 122	
Conventional notations, 87		Homeopathics in pregnancy, 122	
<b>6 Adverse drug reactions and drug interactions</b>	<b>89</b>	Conclusion	123
<i>Maryam Bazargan, Kirsten Small</i>		<b>8 Labour and birth</b>	<b>126</b>
Introduction	90	<i>Clare Davison, Roslyn Donnellan-Fernandez</i>	
6.1 Adverse drug reactions	90	Introduction	127
Risk factors for developing an adverse drug reaction, 90		8.1 Physiology of labour and birth	127
Incidence of adverse drug reactions, 91		8.2 Overview of drugs used during labour	128
Classification of adverse drug reactions, 91		8.3 Uterotonics	128
Drug allergy, 91		Oxytocics, 128	
6.2 Drug interactions	92	Ergot alkaloids, 130	
Frequency of drug interactions, 92		Prostaglandins, 131	
Classification of drug interactions, 93		Antifibrinolytic and haemostatic agents, 132	
Absorption, 93		Tocolytics, 133	
Distribution, 94		8.4 The pathophysiology of pain	133
Metabolism, 94		The experience of pain, 135	
Excretion, 95		The gate control theory, 135	
Drug interactions with nutrients and CAMs, 95		Non-pharmacological pain management: sterile water injections, 137	
<b>PART 3</b>		8.5 Pharmacological relief of pain	138
<b>Pharmacology across the childbearing continuum</b>	<b>98</b>	Paracetamol, 138	
<b>7 Pregnancy</b>	<b>98</b>	Opioids, 138	
<i>Clare Davison, Roslyn Donnellan-Fernandez</i>		Clinical considerations when using opiates during labour and birth, 140	
7.1 Overview of the female reproductive system controls and hormones	99	Morphine, 141	
The ‘puberty clock’, 99		Fentanyl, 144	
The menstrual cycle, 99		8.6 Inhalation agents	144
		Nitrous oxide, 145	
		Methoxyflurane, 146	



8.7 Local anaesthetic	147		
Chemistry and dissociation of local anaesthetic drugs,	147		
Esters and amides,	147		
Mechanism of action,	147		
Pharmacokinetics,	148		
Use of a vasoconstrictor,	149		
Parenterals,	149		
Central nerve block: epidural anaesthesia,	150		
Dermatome assessment,	151		
Epidural (extradural) anaesthesia,	152		
Patient controlled epidural analgesia,	152		
Central nerve block: spinal (subarachnoid) anaesthesia,	152		
Combined spinal/epidural analgesia,	153		
Adverse drug reactions,	153		
8.8 General anaesthetic	153		
Inhalation anaesthetics,	153		
IV anaesthetic agents,	154		
Ultrashort-acting barbiturates,	155		
Conclusion	156		
<b>9 The postnatal period</b>	<b>159</b>		
<i>Clare Davison, Roslyn Donnellan-Fernandez</i>			
Introduction	160		
9.1 Analgesia	160		
Paracetamol,	161		
Non-steroidal anti-inflammatory drugs (NSAIDs),	161		
Opioids,	162		
9.2 Infection, bladder and bowel care	163		
Perineal trauma and repair,	163		
Bladder and bowel care,	163		
9.3 Postnatal contraception	164		
Contraception for women,	164		
Hormone components of COC formulations,	166		
Counselling points,	170		
Oral COC formulations,	170		
Emergency contraception,	173		
Non-oral hormonal contraception,	174		
Long-acting reversible contraceptives,	174		
Non-drug contraceptive methods,	176		
Failure of contraception,	177		
9.4 Postnatal mental health	180		
9.5 Complementary and alternative medicine	180		
Conclusion	181		
<b>10 The newborn and lactation</b>	<b>183</b>		
<i>Roslyn Donnellan-Fernandez, Clare Davison</i>			
Introduction	185		
10.1 Use of medicines while breastfeeding	185		
Safe drug therapy during lactation,	185		
10.2 Pharmacology and breastfeeding	186		
Anatomical overview and physiology – mammary glands,	186		
Hormones and lactation,	186		
Lactation promoters and inhibitors,	187		
Passage of drugs into breast milk,	188		
Passive diffusion,	189		
Active transport,	190		
10.3 Pharmacokinetics in infants	190		
Drug risk in breastfed infants,	191		
Potential drug interactions and adverse effects between prescribed medications and breast milk,	191		
Drug interactions with prescription medication,	192		
Adverse effects of recreational drugs while breastfeeding,	192		
Medication for which there is limited evidence of long-term effects,	196		
Drugs and breastfeeding guidelines,	196		
10.4 Online clinical protocols and classification systems	197		
Classification systems for the safety of drugs in lactation,	197		
Management and treatment: inflammatory mastitis and bacterial mastitis,	199		
Complementary medicines and breastfeeding recommendations,	200		
Principles of safe prescribing to neonates,	203		
Conclusion	207		
<b>11 Vaccinations in pregnancy and recommended schedule for newborns</b>	<b>211</b>		
<i>Michelle Gray, Roslyn Donnellan-Fernandez, Kirsten Small</i>			
Introduction	213		
11.1 The immune system	213		
Innate immunity,	213		
Adaptive immunity,	213		
Primary immune response and immunological memory,	215		
Secondary immune response,	215		
Active vs artificially acquired immunity,	216		
11.2 Vaccines given during pregnancy	219		
Types of vaccine,	219		
Whole-cell vaccines,	220		
Subunit vaccines,	223		
New vaccine type: nucleic acid vaccines,	225		
11.3 Vaccine schedules	226		
Primary series,	226		
Boosters,	226		
Annual influenza vaccine,	226		
Herd immunity,	227		
11.4 Clinical considerations	227		
Vaccine cold chain management,	227		
Vaccine administration technique,	227		
Using body landmarks to administer intramuscular vaccines,	228		

Administering a vaccine into the vastus lateralis (anterolateral thigh), 229	
Administering a vaccine into the deltoid, 229	
Reporting vaccinations to national registers, 230	
Vaccine side effects, 230	
Conclusion: The future of vaccines	230
<b>PART 4</b>	
<b>Pharmacology for special considerations</b>	<b>234</b>
<b>12 Infection and sepsis – maternal and neonatal</b>	<b>234</b>
<i>Michelle Gray, Roslyn Donnellan-Fernandez</i>	
Introduction	235
12.1 Aetiology of infection	235
12.2 Pathogens	236
Bacteria, 237	
Viruses, 239	
Fungi, 239	
Parasites, 239	
Algae, 240	
12.3 Infections during pregnancy	240
Bacterial infection, 240	
Viral infection, 242	
Parasitic infection, 243	
12.4 Treatments	244
Antibacterial medications, 244	
Antivirals, 247	
Antifungals, 247	
Parasitic infection treatment, 248	
12.5 The microbiome and complementary and alternative medicine (CAM) considerations	248
CAM considerations, 248	
Conclusion	250
<b>13 Diabetes in pregnancy and its management</b>	<b>254</b>
<i>Maryam Bazargan, Kirsten Small, Roslyn Donnellan-Fernandez</i>	
Introduction	255
13.1 Pancreatic hormones and diabetes mellitus	256
Insulin from the pancreas, 256	
Diabetes mellitus, 256	
Blood glucose monitoring, 260	
13.2 Management of gestational diabetes	261
Drugs for gestational diabetes, 261	
Insulin, 261	
Insulin formulations, 261	
Insulin administration, 263	
13.3 Management of type 2 diabetes	265
Drugs for type 2 diabetes, 265	
Metformin, 265	
OHAs not used in pregnancy, 266	
Hypoglycaemia, 268	
<b>14 The thyroid</b>	<b>272</b>
<i>Kirsten Small, Maryam Bazargan</i>	
Introduction	273
14.1 Thyroid hormones	273
Synthesis, storage and secretion, 273	
Regulation, 274	
Mechanism of thyroid hormone actions, 277	
14.2 Thyroid physiology and pregnancy	277
Pharmacotherapy of thyroid disorders, 277	
Hypothyroidism, 278	
Hyperthyroidism (thyrotoxicosis), 281	
Iodine/iodide, 283	
Radioactive iodine, 284	
<b>15 Drugs affecting the heart, vascular system and blood volume</b>	<b>286</b>
<i>Maryam Bazargan, Kirsten Small</i>	
15.1 Introduction: The heart	287
Control by the autonomic nervous system, 287	
The cardiac conduction system, 289	
The vascular system, 291	
The renin–angiotensin–aldosterone system, 291	
The sympathetic nervous system, 292	
15.2 Hypertension in pregnancy	295
Drug therapy for hypertension in pregnancy, 296	
Calcium channel blockers, 297	
$\beta$ -adrenoceptor antagonists, 299	
Non-selective $\alpha_1$ - and $\beta$ -adrenoceptor antagonists, 299	
Direct-acting vasodilators, 303	
Centrally acting adrenergic inhibitors, 303	
<b>16 Blood and blood clotting</b>	<b>306</b>
<i>Kirsten Small, Maryam Bazargan</i>	
Introduction	307
16.1 Blood composition	307
Blood cell production, 307	
16.2 Physiological changes in the haemopoietic system in pregnancy and the puerperium	309
Anaemia, 309	
Iron deficiency and iron deficiency anaemia, 310	
Folic acid and vitamin B12, 311	
16.3 Blood clotting	312
The haemostatic mechanism, 312	
16.4 Physiological changes in the coagulation system in pregnancy and the puerperium	313
Thromboembolic disorders and pregnancy, 313	
Placental function disorders and thrombophilias, 313	
Anticoagulation and pregnancy, 314	
Bleeding disorders and pregnancy, 315	



16.5 Anticoagulant drugs	315	18.4 Bronchodilator drugs	348
Fondaparinux: Antithrombin-III-dependent anticoagulant, 320		$\beta$ -adrenoceptor agonists, 348	
16.6 Antiplatelet agents	321	Methylxanthines, 350	
Aspirin, 321		Anticholinergics, 352	
16.7 Haemostatic and antifibrinolytic drugs	321	18.5 Prophylactic antiasthma drugs (preventers)	352
Tranexamic acid, 321		Corticosteroids, 352	
Protamine (reverses heparin's action), 322		Mechanism of action, 352	
Vitamin K (reverses warfarin's action), 322		Systemic administration and adverse effects, 353	
		Glucocorticoid resistance, 353	
<b>17 Premature labour and birth</b>	<b>324</b>	18.6 Other drug groups	354
<i>Michelle Gray, Roslyn Donnellan Fernandez</i>		Leukotriene-receptor antagonists (LTRAs), 354	
Introduction	325	New drugs for asthma, 354	
17.1 Prematurity definitions and causes	325	Drugs to be used with caution for pregnant and postpartum women with asthma, 354	
Premature labour, 325		18.7 Therapies and management of asthma in pregnancy	355
Premature birth, 325		Combination therapy, 355	
Causes of prematurity, 326		Suboptimal therapy, 355	
17.2 Diagnosis of premature labour	327	Stepwise management, 355	
Signs and symptoms of premature labour, 327		Chronic asthma, 355	
A transvaginal ultrasound scan of the cervix in the mid-trimester, 327		Acute asthma, 355	
Assessments that assist in diagnosis, 328		Asthma action plans, 355	
Transfer of the mother and fetus in utero, 329			
17.3 Medications in the management of preterm labour and premature birth	329	<b>19 Mental health</b>	<b>359</b>
Antibiotic therapy, 329		<i>Kirsten Small, Maryam Bazargan, Roslyn Donnellan-Fernandez</i>	
Corticosteroids, 329		Introduction: Mental health and illness	360
Uterotonics and tocolytics, 329		Mental illness in the childbearing year, 360	
Calcium channel blockers, 329		Mental illness in Indigenous populations, 361	
Second-line tocolytics – Cydoxygenase inhibitors, 331		19.1 Pathophysiology of mental health disorders	361
Atosiban (Tractocile), 333		Monoamine neurotransmitters, 362	
Progesterone, 333		19.2 Approaches to therapy	362
17.4 Complementary and alternative therapies	333	Non-drug therapy, 362	
Dietary supplementation, 334		Pharmacotherapy, 363	
Conclusion	334	Informed decision making in mental illness, 364	
		Discontinuation of therapy and rebound effects, 364	
<b>18 Asthma</b>	<b>337</b>	19.3 Anxiety	365
<i>Kirsten Small, Michelle Gray</i>		Anxiety in the childbearing year, 365	
Introduction: The respiratory system, asthma and its treatment	338	Benzodiazepines, 365	
18.1 Control of respiration	338	19.4 Depression	367
Regulation of the glands and musculature of the respiratory tract, 338		Depression in the childbearing year, 367	
18.2 Asthma – An overview	339	Antidepressant drugs, 367	
Pathophysiology of asthma, 340		Antidepressant drug therapy: clinical aspects, 368	
Asthma in pregnancy, 341		Tricyclic antidepressants, 369	
Asthma and lactation, 342		Monoamine oxidase inhibitor antidepressants, 369	
Drugs used in asthma, 342		Selective serotonin reuptake inhibitors, 369	
18.3 Considerations for drug delivery to the airways	344	Serotonin noradrenaline reuptake inhibitors, 369	
Aerosols, 344		Adverse drug reactions of antidepressants, 370	
Inhaled drugs, 345		Serotonin syndrome, 370	
		Drug interactions, 371	
		19.5 Posttraumatic stress disorder	371
		Bipolar affective disorder, 372	
		Lithium: the antimanic drug, 372	

19.6 Postpartum psychosis	374		
Antipsychotic agents, 374			
Drug interactions, 376			
<b>20 Epilepsy</b>	<b>379</b>		
<i>Kirsten Small, Maryam Bazargan, Roslyn Donnellan-Fernandez</i>			
Introduction	380		
Classification of seizures, 380			
Triggers to seizures, 383			
20.1 Antiepileptic drug therapy	383		
Clinical aspects, 383			
Monotherapy and subsequent therapy, 384			
Choice of antiepileptic drug, 384			
Drug-resistant epilepsy, 384			
Status epilepticus, 384			
Medication adherence and therapeutic drug monitoring, 384			
Discontinuing antiepileptic therapy, 384			
Principles of epilepsy management for women in their reproductive years, 385			
AEDs and teratogenesis, 385			
AEDs and neurobehavioural effects for the infant, 385			
Contraception, 386			
Pregnancy and epilepsy, 386			
The puerperium and epilepsy, 386			
Eclampsia, 387			
20.2 Antiepileptic drugs	387		
The ideal antiepileptic drug, 387			
General considerations, 388			
Antiepileptic hypersensitivity syndrome, 389			
Drug interactions, 389			
20.3 Mechanisms of action of currently used antiepileptics	389		
Antiepileptics that enhance GABA inhibition, 389			
Antiepileptics that inhibit sodium channel function, 390			
Antiepileptics that act by other mechanisms, 393			
Conclusion	394		
<b>21 Drugs of dependence</b>	<b>397</b>		
<i>Kirsten Small, Roslyn Donnellan-Fernandez, Maryam Bazargan</i>			
Introduction	398		
21.1 Drug abuse and misuse	398		
Drug dependence, 398			
Withdrawal syndromes, 399			
Patterns of drug abuse in Australia, 399			
Patterns of drug abuse in New Zealand, 399			
Drug abuse during pregnancy and breastfeeding, 399			
21.2 Central nervous system stimulants	400		
Caffeine and the xanthine alkaloids, 400			
Nicotine and tobacco smoking, 401			
Amphetamines, 402			
21.3 Dependence on opioids	404		
Opioid abuse and dependence, 404			
Opioid dependence and pregnancy, 404			
Managing women with pharmacological dependence on opioids, 405			
Methadone or buprenorphine maintenance, 405			
Acute overdosage, 406			
Analgesia for women with opioid abuse disorders, 406			
21.4 Alcohol	406		
Ethanol (ethyl alcohol, 'alcohol'), 407			
Pharmacological mechanisms and actions of ethanol, 407			
Hangover and alcohol withdrawal syndrome, 409			
21.5 Cannabis drugs (marijuana, hashish)	409		
Preparations and active constituents, 409			
Administration and pharmacokinetics, 409			
Mechanism and pharmacological effects, 409			
Medical uses of cannabinoids, 410			
<b>22 Role of the midwife</b>	<b>413</b>		
<i>Roslyn Donnellan-Fernandez, Clare Davison, Michelle Gray, Maryam Bazargan, Kirsten Small</i>			
Introduction	414		
Scope of practice, 415			
International prescribing context, 415			
22.1 Governance of midwifery prescribing	415		
Midwifery prescriptive authority in New Zealand, 415			
Midwifery prescriptive authority in Australia, 416			
22.2 Educational preparation for prescribing	417		
Australian requirements for endorsement for scheduled medicines as a midwife, 418			
22.3 Legislation and regulations impacting prescribing and medication management	419		
Criminal law, 419			
Civil law, 419			
Commonwealth legislation, 419			
State or territory legislation, 419			
Regulation of midwifery prescribing, 419			
Australian midwifery framework, 419			
22.4 Quality and safety	422		
Quality use of medicines, 422			
Prescribing practice: ensuring quality and safety, 422			
Health profession prescribing pathway, 422			
NPS medicinewise prescribing competencies framework, 422			
Person-centred use of medicines, 423			
National safety and quality standards: Medication management, 432			
22.5 Role of the midwife in prescribing	433		
Consultation, referral and collaboration, 433			



Pharmaceutical benefits scheme prescribing by midwives, 434

22.6 Additional professional obligations for midwives

Continuing professional development, 437

437

Professional indemnity insurance, 437  
Complaints, 438

Conclusion

439

Index

443